PMCB - PharmaCyte Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0635
+0.0015 (+2.4194%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.0620
Open0.0611
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0600 - 0.0648
52 Week Range0.0300 - 0.1700
Volume1,658,944
Avg. Volume2,856,033
Market Cap61.796M
Beta2.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire6 days ago

    PharmaCyte Biotech Meets with Oncology Advisory Board

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it recently met with its Oncology Advisory Board, which was formed to assist in optimizing and finalizing the clinical protocol and other clinical trial-related matters ...

  • Business Wire12 days ago

    PharmaCyte Biotech Announces Production of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the production of the cells necessary to prepare the Master Cell Bank has started.

  • Business Wire19 days ago

    PharmaCyte Biotech Announces Successful Completion of Cell Testing for Production of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that Eurofins Lancaster Laboratories, a leading Contract Manufacturing Organization that PharmaCyte selected to prepare its Master Cell Bank , has successfully completed its ...

  • Business Wirelast month

    British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it is providing a summary overview, corporate history and status report to address a regulatory compliance request from the British Columbia Securities Commission which, ...

  • Business Wire2 months ago

    PharmaCyte Biotech Update on Shareholder Call

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that during its upcoming shareholder call PharmaCyte’s Chief Executive Officer, Kenneth L.

  • Business Wire2 months ago

    PharmaCyte Biotech to Hold Shareholder Call

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L.

  • Business Wire2 months ago

    PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado , has identified an organism whose genome contains the genetic code for production of an enzyme capable of activating ...

  • Business Wire2 months ago

    PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr.

  • Business Wire3 months ago

    PharmaCyte Biotech Appoints Alan Morell of Creative Management Partners as Strategic Advisor

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Alan Morell, the Chairman and Chief Executive Officer of Creative Management Partners, as a Strategic Advisor to the Chief Executive Officer and Board of ...

  • Business Wire3 months ago

    PharmaCyte Restructures Agreements with Austrianova to Strengthen Partnership

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has reached an agreement with Austrianova to restructure certain agreements between them pursuant to a Binding Term Sheet .

  • ACCESSWIRE3 months ago

    MicroCap Review Magazine Fall 2017 Issue Now Available

    The Digital Issue of the Fall 2017 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / September 5, 2017 / ...